Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Open accessAbstract
Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ratiometric medication combinations supplied by free solution can have their pharmacokinetics and biodistribution altered by smart nanoparticles-based synergistic drug combination delivery.
“For instance, ratiometric medication combinations supplied by free solution can have their pharmacokinetics and biodistribution altered by smart nanoparticles-based synergistic drug combination delivery.334”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [334]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Singh, A., Dilnawaz, F., Mewar, S., Sharma, U., Jagannathan, N. R., & Sahoo, S. K. (2011) · ACS Applied Materials & Interfaces · doi:10.1021/am101196v · Cited by 159 · see citing works
RetractedSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710 · see citing works
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,771 · see citing works
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · see citing works
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · see citing works
The epigenetic progenitor origin of human cancer
Feinberg, A. P., OHLSSON, R. I., & Henikoff, S. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,851 · see citing works
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739 · see citing works
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,583 · see citing works
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,570 · see citing works
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,528 · see citing works
(2016) · Wiley eBooks · doi:10.1002/9781119000822 · Cited by 1,151 · see citing works
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,129 · see citing works
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D. A., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 946 · see citing works
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 772 · see citing works
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693 · see citing works
Site-specific antibody drug conjugates for cancer therapy
Panowski, S. H., Bhakta, S., Raab, H. E., Polakis, P. G., & Junutula, J. R. (2013) · mAbs · doi:10.4161/mabs.27022 · Cited by 677 · see citing works
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · PubMed · Cited by 647 · see citing works
Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs
Torchilin, V. P., Lukyanov, A. N., Gao, Z., & Papahadjopoulos‐Sternberg, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931428100 · Cited by 538 · see citing works
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 516 · see citing works
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y. F., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 515 · see citing works
Cancer epigenomics: beyond genomics
Sandoval, J., & Esteller, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.008 · Cited by 474 · see citing works
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S. V., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 474 · see citing works
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398 · see citing works
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390 · see citing works
Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display
Montet, X., Funovics, M. A., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388 · see citing works
Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy
Dilnawaz, F., Singh, A., Mohanty, C., & Sahoo, S. K. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.057 · Cited by 385 · see citing works
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 378 · see citing works
Tardi, P. G., Johnstone, S. A., Harasym, N. L., Xie, S., Harasym, T. O., Zisman, N., Harvie, P., Bermudes, D. G., & Mayer, L. D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 357 · see citing works
Cancer gene therapy: fringe or cutting edge?
McCormick, F. P. (2001) · Nature reviews. Cancer · doi:10.1038/35101008 · Cited by 345 · see citing works
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340 · see citing works
Maeda, H., Tsukigawa, K., & Fang, J. Q. (2015) · Microcirculation · doi:10.1111/micc.12228 · Cited by 336 · see citing works
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A. M., Deshpande, P. P., & Torchilin, V. P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 335 · see citing works
Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 332 · see citing works
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C. E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310 · see citing works
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S. E., Parker, S. K., Thornton, C. E., et al. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub3 · Cited by 307 · see citing works
Treat, L. H., McDannold, N. J., Zhang, Y., Vykhodtseva, N. I., & Hynynen, K. (2012) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.04.015 · Cited by 296 · see citing works
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285 · see citing works
Soma, C. E., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281 · see citing works
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 258 · see citing works
Self-citationKummar, S., Chen, H. X., Wright, J., Holbeck, S. L., Millin, M. D., Tomaszewski, J. E., Zweibel, J., Collins, J. M., & Doroshow, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3216 · Cited by 249 · see citing works
New Horizons for Old Drugs and Drug Leads
Cragg, G. M. L., Grothaus, P. G., & Newman, D. J. (2014) · Journal of Natural Products · doi:10.1021/np5000796 · Cited by 247 · see citing works
Mamot, C., Ritschard, R., WICKI, A. N., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. F. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244 · see citing works
Lammers, T., Šubr, V., Ulbrich, K., Peschke, P., Huber, P. E., Hennink, W. E., & Storm, G. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.040 · Cited by 240 · see citing works
Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus, E., Fallowfield, L. J., Kyriakides, S., Costa, A., Čufer, T., Albain, K. S., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp235 · Cited by 239 · see citing works
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 214 · see citing works
Wong, H. L., Bendayan, R., Rauth, A. M., & Wu, X. Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.09.007 · Cited by 208 · see citing works
Self-citationRecent advances in delivery of drug–nucleic acid combinations for cancer treatment
Li, J., Wang, Y., Zhu, Y. T., & Oupický, D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.010 · Cited by 207 · see citing works
Gene and doxorubicin co-delivery system for targeting therapy of glioma
Liu, S., Guo, Y., Huang, R., Li, J., Huang, S., Kuang, Y., Han, L., & Jiang, C. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.031 · Cited by 203 · see citing works
Lipid-Based Nanocarriers for RNA Delivery
Xue, H. Y., Guo, P., Wen, W., & Wong, H. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531164540 · Cited by 202 · see citing works
Self-citationMolecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197 · see citing works
Combination Drug Delivery Approaches in Metastatic Breast Cancer
Lee, J. H., & Nan, A. (2012) · Journal of Drug Delivery · doi:10.1155/2012/915375 · Cited by 193 · see citing works
Qian, X., Long, L., Shi, Z., Liu, C., Qiu, M., Sheng, J., Pu, P., Yuan, X., Ren, Y., & Kang, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.039 · Cited by 186 · see citing works
American Society of Clinical Oncology (ASCO)
Zhang, Y. (2008) · Encyclopedia of Global Health · doi:10.4135/9781412963855.n89 · Cited by 186 · see citing works
Wong, H. L., Bendayan, R., Rauth, A. M., et al. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20100 · Cited by 178 · see citing works
Self-citationElBayoumi, T. A., & Torchilin, V. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2392 · Cited by 170 · see citing works
Combination immunotherapy approaches
Drake, C. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds262 · Cited by 167 · see citing works
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 167 · see citing works
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., Yasuda, J., Obata, K., Kikuchi, H., Ishida, T., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.037 · Cited by 165 · see citing works
Smart Polymeric Nanoparticles for Cancer Gene Delivery
Lin, G., Zhang, H., & Huang, L. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500656v · Cited by 164 · see citing works
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7000 · Cited by 164 · see citing works
Epigenetic mechanisms of importance for drug treatment
Ivanov, M., Barragán, I., & Ingelman‐Sundberg, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.004 · Cited by 159 · see citing works
Wadhwa, D., Fallah‐Rad, N., Grenier, D., Krahn, M., Fang, T., Ahmadie, R., Walker, J. R., Lister, D., Arora, R. C., Barač, I., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0260-6 · Cited by 155 · see citing works
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Zeglinski, M. R., Lüdke, A., Jassal, D. S., & Singal, P. K. (2011) · Europe PMC (PubMed Central) · Cited by 151 · see citing works
Cai, L., Xu, G., Shi, C., Guo, D., Wang, X., & Luo, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.044 · Cited by 151 · see citing works
Dai, X., & Tan, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.010 · Cited by 148 · see citing works
Joensuu, H., Holli, K. A., Heikkinen, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3720 · Cited by 145 · see citing works
Sun, X., Pang, Z., Ye, H., Qiu, B., Guo, L., Li, J., Ren, J., Qian, Y. J., Zhang, Q., Chen, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.035 · Cited by 139 · see citing works
Poon, C. J., He, C., Liu, D., Lu, K., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.026 · Cited by 132 · see citing works
He, C., Liu, D., & Lin, W. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.017 · Cited by 129 · see citing works
Li, S.-Y., Sun, R., Wang, H., Shen, S., Liu, Y., Du, X., Zhu, Y., & Jun, W. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.011 · Cited by 128 · see citing works
Alba, E., Martín, M., Ramos, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.125 · Cited by 128 · see citing works
Milane, L. S., Ganesh, S., Shah, S., Duan, Z., & Amiji, M. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.032 · Cited by 127 · see citing works
Imaging of Vx‐2 rabbit tumors with ανβ3‐integrin‐targeted 111In nanoparticles
Hu, G., Lijowski, M., Zhang, H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22581 · Cited by 126 · see citing works
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs
Shin, H.-C., Alani, A. W. G., Cho, H., Bae, Y., Kolesar, J. M., & Kwon, G. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000549 · Cited by 126 · see citing works
Mouse models for studying angiogenesis and lymphangiogenesis in cancer
Eklund, L., Bry, M., & Alitalo, K. K. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.007 · Cited by 124 · see citing works
Tardi, P. G., Santos, N. D., Harasym, T. O., Johnstone, S. A., Zisman, N., Tsang, A. W., Bermudes, D. G., & Mayer, L. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0243 · Cited by 122 · see citing works
Fang, J., Lai, Y., Chiu, T., Chen, Y., Hu, S., & Chen, S. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300598 · Cited by 120 · see citing works
Shuhendler, A. J., Cheung, R. Y., Manias, J. L., Connor, A., Rauth, A. M., & Wu, X. Y. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0271-3 · Cited by 118 · see citing works
Self-citationSingle agent versus combination chemotherapy for metastatic breast cancer
Carrick, S. E., Parker, S. K., Thornton, C. E., et al. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub2 · Cited by 118 · see citing works
Milane, L. S., Duan, Z., & Amiji, M. M. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.12.009 · Cited by 116 · see citing works
Epigenomes as therapeutic targets
Hamm, C. A., & Costa, F. F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.003 · Cited by 114 · see citing works
Xiao, H., Li, W., Qi, R., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.004 · Cited by 114 · see citing works
Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
Zhang, G., Park, M. A., Mitchell, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0469 · Cited by 113 · see citing works
Gu, H., Liu, Zhang, J., Sun, Xie, & Xia (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s28088 · Cited by 111 · see citing works
Shuhendler, A. J., Prasad, P., Leung, M. Y. K., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200006 · Cited by 111 · see citing works
Self-citationLi, Y., Abbaspour, M., Grootendorst, P. V., et al. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.04.028 · Cited by 101 · see citing works
Kong, F., Wang, W., Xi, M., Duan, X., & Wang, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80297 · Cited by 100 · see citing works
Yin, Q., Shen, J., Chen, L., Zhang, Z., Gu, W., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.039 · Cited by 100 · see citing works
Mullard, A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4239 · Cited by 97 · see citing works
Zhang, R., Cai, P., Zhang, T., Chen, K., Li, J., Cheng, J., Pang, K. S., Adissu, H. A., Rauth, A. M., & Wu, X. Y. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.383 · Cited by 96 · see citing works
Self-citationSalzano, G., Navarro, G., Trivedi, M. S., Rosa, G. D., & Torchilin, V. P. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0556 · Cited by 92 · see citing works
Salzano, G., Riehle, R. D., Navarro, G., Perche, F., Rosa, G. D., & Torchilin, V. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.037 · Cited by 91 · see citing works
Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery
Wu, X. Y. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1165662 · Cited by 91 · see citing works
Self-citationLi, Y., Taulier, N., Rauth, A. M., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9033-2 · Cited by 87 · see citing works
Improving Delivery and Efficacy of Nanomedicines in Solid Tumors: Role of Tumor Priming
Wang, J., Lu, Z., Gao, Y., Wientjes, M. G., & Au, J. L. ‐. (2011) · Nanomedicine · doi:10.2217/nnm.11.141 · Cited by 85 · see citing works
Harasym, T. O., Tardi, P. G., Harasym, N. L., Harvie, P., Johnstone, S. A., & Mayer, L. D. (2006) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000006783980937 · Cited by 84 · see citing works
Hasenstein, J. R., Shin, H., Kasmerchak, K., Buehler, D. G., Kwon, G. S., & Kozak, K. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0987 · Cited by 83 · see citing works
Prasad, P., Shuhendler, A. J., Cai, P., Rauth, A. M., & Wu, X. Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.008 · Cited by 83 · see citing works
Self-citationVijayaraghavalu, S., Peetla, C., Lu, S., & Labhasetwar, V. D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300281t · Cited by 82 · see citing works
Vijayaraghavalu, S., Dermawan, J. K. T. K., Cheriyath, V., & Labhasetwar, V. D. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3004622 · Cited by 82 · see citing works
Luker, G. D., & Piwnica-Worms, D. (2001) · Academic Radiology · doi:10.1016/s1076-6332(03)80738-9 · Cited by 81 · see citing works
Xue, H. Y., & Wong, H. L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.029 · Cited by 80 · see citing works
Self-citationHamilton, G. S. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.05.006 · Cited by 76 · see citing works
Current Cancer Treatment - Novel Beyond Conventional Approaches
(2011) · InTech eBooks · doi:10.5772/897 · Cited by 75 · see citing works
Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz‐Esparza, G. U., González-Delgado, C. A., Cara, F. E., Granados-Principal, S. M., Evans, K. W., Akçakanat, A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.27 · Cited by 73 · see citing works
Chiang, C., Hu, S., Liao, B., Chang, Y., & Chen, S.-Y. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.07.009 · Cited by 71 · see citing works
Nanoparticles for gene delivery: therapeutic and toxic effects
Choi, Y., Lee, M., David, A. E., & Park, Y. S. (2014) · Molecular & Cellular Toxicology · doi:10.1007/s13273-014-0001-3 · Cited by 69 · see citing works
Kirtane, A. R., & Panyam, J. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.234 · Cited by 65 · see citing works
Su, X., Wang, Z., Li, L., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300675c · Cited by 62 · see citing works
Shuhendler, A. J., Prasad, P., Zhang, R., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500093c · Cited by 60 · see citing works
Self-citationSchmid, D., Jarvis, G. E., Fay, F., Small, D. M., Greene, M. K., Majkut, J., Spence, S., McLaughlin, K. M., McCloskey, K. D., Johnston, P. G., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.413 · Cited by 56 · see citing works
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55 · see citing works
Shin, H.-C., Cho, H., Lai, T. C., Kozak, K. R., Kolesar, J. M., & Kwon, G. S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.024 · Cited by 53 · see citing works
Jin, C. S., Qian, N., Zhao, W., et al. (2010) · Biomacromolecules · doi:10.1021/bm1005992 · Cited by 53 · see citing works
Liu, Z., Wu, X. Y., & Bendayan, R. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9803353 · Cited by 53 · see citing works
Self-citationMamot, C., Ritschard, R., WICKI, A. N., Küng, W., Schuller, J. C., Herrmann, R., & Rochlitz, C. F. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.680960 · Cited by 52 · see citing works
Zhang, M., Garbuzenko, O. B., Reuhl, K. R., et al. (2012) · Nanomedicine · doi:10.2217/nnm.11.131 · Cited by 51 · see citing works
Guo, D., Hong, S., Jiang, H., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.011 · Cited by 49 · see citing works
Monoclonal antibody‐targeted polymeric nanoparticles for cancer therapy – future prospects
Goodall, S., Jones, M. L., & Mahler, S. M. (2014) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4555 · Cited by 46 · see citing works
Nanoparticle-Based Combination Therapy for Cancer Treatment
Yhee, J. Y., Son, S., Lee, H., & Kim, K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531165059 · Cited by 45 · see citing works
Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies
Catarina, A., Nuno, J., & Simões, S. (2011) · InTech eBooks · doi:10.5772/22656 · Cited by 44 · see citing works
Liu, Z., Ballinger, J. R., Rauth, A. M., et al. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021567 · Cited by 44 · see citing works
Megerdichian, C., Olimpiadi, Y. B., & Hurvitz, S. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.001 · Cited by 42 · see citing works
Paclitaxel Tumor-Priming Enhances siRNA Delivery and Transfection in 3-Dimensional Tumor Cultures
Wong, H. L., Shen, Z., Lu, Z., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1004383 · Cited by 42 · see citing works
Self-citationWaterhouse, D., Gelmon, K. A., Klasa, R. J., Chi, K., Huntsman, D. D., Ramsay, E., Wasan, E. K., Edwards, L., Tucker, C., Zastre, J. A., et al. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778194586 · Cited by 42 · see citing works
Prasad, P., Cheng, J., Shuhendler, A. J., et al. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0051-1 · Cited by 41 · see citing works
Heparin-folate-retinoic acid bioconjugates for targeted delivery of hydrophobic photosensitizers
Tran, T. H., Bae, B.-C., Lee, Y.-K., Na, K., & Huh, K. M. (2012) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.10.075 · Cited by 39 · see citing works
Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin, S. F. (2012) · PubMed · Cited by 39 · see citing works
Cancello, G., Bagnardi, V., Sangalli, C., et al. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.03.002 · Cited by 38 · see citing works
Masuda, N., Higaki, K., Takano, T., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2492-y · Cited by 37 · see citing works
Batist, G., Sawyer, M. B., Gabrail, N., Christiansen, N., Marshall, J. L., Spigel, D. R., & Louie, A. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4108 · Cited by 37 · see citing works
Huang, Y.-H., Cai, T.-G., Xia, X., Cai, Y., & Wu, X.-Y. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3sg7k · Cited by 36 · see citing works
Self-citationSequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy
Pandey, A., Kulkarni, A. A., Roy, B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3783 · Cited by 34 · see citing works
Future Approaches in Immunotherapy
Rini, B. I. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.005 · Cited by 31 · see citing works
Advancements in the delivery of epigenetic drugs
Cramer, S. A., Adjei, I. M., & Labhasetwar, V. D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1021678 · Cited by 31 · see citing works
On the Synergistic Effect of Doxorubicin and Mitomycin C Against Breast Cancer Cells
Shuhendler, A. J., O'Brien, P. J., Rauth, A. M., et al. (2007) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2007.22.4.201 · Cited by 30 · see citing works
Suppression of Microbunching Instability Using Bending Magnets in Free-Electron-Laser Linacs
Qiang, J., Mitchell, C. E., & Venturini, M. (2013) · Physical Review Letters · doi:10.1103/physrevlett.111.054801 · Cited by 30 · see citing works
CHEUNG, R., Rauth, A. M., Ronaldson, P. T., et al. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.09.011 · Cited by 29 · see citing works
Lu, S., & Labhasetwar, V. D. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0113-z · Cited by 25 · see citing works
Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy
Luo, S., Gu, Y., Zhang, Y., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500867g · Cited by 24 · see citing works
Dicko, A., Frazier, A. A., Liboiron, B. D., Hinderliter, A. K., Ellena, J. F., Xie, X., Cho, C., Weber, T., Tardi, P. G., Cabral-Lilly, D., et al. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9561-z · Cited by 23 · see citing works
Pignata, S., Pujade-Lauraine, É., du Bois, A., et al. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.08.004 · Cited by 17 · see citing works
Shuhendler, A. J., Prasad, P., Cai, P., Hui, K. K., Henderson, J. T., Rauth, A. M., & Wu, X. Y. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.01.005 · Cited by 16 · see citing works
Self-citation(2015) · Nature · doi:10.1038/518273a · Cited by 14 · see citing works
Gene therapy approaches to enhance bioreductive drug treatment
Cowen, R. L., Garside, E., Fitzpatrick, B., Papadopoulou, M. V., & Williams, K. J. (2008) · British Journal of Radiology · doi:10.1259/bjr/55070206 · Cited by 11 · see citing works
Combination of Chemopreventive Agents in Nanoparticles for Cancer Prevention
Yang, C. S., Wang, H., & Hu, B. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0312 · Cited by 10 · see citing works
Stewart, D. J., Nunez, M. I., Jelı́nek, J., Hong, D. S., Gupta, S. K., Issa, J. J., Wistuba, I. I., & Kurzrock, R. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-2 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [4]Chabner BA Thompson EC Modalities of Cancer Therapy Merck Mannual Professional Edition http://www.merckmanuals.com/professional/hematology-and-oncology/principles-of-cancer-therapy/modalities-of-cancer-therapy
- [152]Zhou Y Abbasi AZ He C Ni J Cai Y Guo X Wu XY A simple and effective numerical method for quantifying drug release from nano-/microparticles inside dialysis tubing 42nd Symposium of Controlled Release Society 2015
Cited by
Sorted by citations
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178 · see citing works
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115 · see citing works
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51 · see citing works
Chen, J., Liu, Z., Fang, H., Su, Q., Fan, Y., Song, L., & He, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05151-5 · Cited by 10 · see citing works
- Authors
- Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y.
- Affiliations
- Temple University (US)
- University of Toronto (CA)
- Corresponding author
- Wu, Xiao Yu
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 240
- Pages
- 489-503
- ISSN
- 0168-3659 (ISSN-L)
- PMC
- PMC5064882
- OpenAlex
- W2417973730
- Cited by
- 380
- References
- 149
- Citations by year
- 2026: 24 · 2025: 45 · 2024: 57 · 2023: 45 · 2022: 40 · 2021: 40 · 2020: 47 · 2019: 34 · 2018: 25 · 2017: 18 · 2016: 4
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Canadian Breast Cancer Foundation
- University of Toronto Open Scholarship
- National Institute of Health/National Cancer Institute (R01CA168917)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- nanomedicine, synergistic drug combination, combination cancer therapy, nanocarriers, drug delivery, anticancer agents, small molecule drugs, biologics
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Drug Carriers, Drug Synergism, Humans, Neoplasms, Genetic Therapy, Nanostructures, Nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
